DOCS Stock Up in Pre-Market Post Q1 Earnings Beat, Gross Margin Down
Doximity beats first-quarter fiscal 2026 estimates with double-digit revenue growth and lifts its full-year forecast.
Doximity, Inc. (DOCS) Q1 2026 Earnings Call Transcript
Doximity, Inc. (NYSE:DOCS ) Q1 2026 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Anna Bryson - Chief Financial Officer Jeffrey A. Tangney - Co-Founder, CEO & Chairperson ...
2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run
It's been a wild first half of the year for stocks in 2025, but finding the right companies for your portfolio is a very personal process. You need to consider the type of stocks you want to buy, t...
New Doximity Study Shows Modest Physician Pay Growth Amid Deeper Workforce Strain, Reimbursement Pressures
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today released its 2025 Physician Compensation Report. The findings highlig...
Doximity (DOCS) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Doximity (DOCS) closed at $59.7, marking a -2.13% move from the previous day.
Doximity: Slowing Sales And EBITDA Growth
Doximity shares have dropped nearly 25% from February highs, despite strong Q4 earnings and 17% revenue growth year-over-year. Analyst sentiment is mixed, and insider selling has notably increased ...
Doximity (DOCS) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, Doximity (DOCS) stood at $59.38, denoting a -1.44% move from the preceding trading day.
Doximity (DOCS) Rises Higher Than Market: Key Facts
Doximity (DOCS) concluded the recent trading session at $61.55, signifying a +2.24% move from its prior day's close.
Dr Martens tiptoes higher after positive America retail trading, UK still challenging
Dr Martens PLC (LSE:DOCS) said trading since the start of the financial year has been in line with expectations, with guidance for its current financial year unchanged and profit expected to be wei...
Doximity (DOCS) Laps the Stock Market: Here's Why
Doximity (DOCS) concluded the recent trading session at $61.09, signifying a +1.13% move from its prior day's close.
Does DOCS' Shift Toward Enterprise Offerings Signal a Long-Term Pivot?
DOCS sharpens its enterprise focus with AI and workflow tools, signaling a deeper pivot beyond pharma marketing roots.
Doximity Declines 4.4% in a Month: How to Play the Stock Now?
Over the past month, Doximity's DOCS shares have lost approximately 4.4% despite the company reporting solid fourth-quarter fiscal 2025 results with $138.3 million in revenues and a 50% adjusted EB...
Dr Martens surges 23% as investors lace up for recovery story
Shares in Dr Martens PLC (LSE:DOCS) jumped 23% on Thursday after the bootmaker delivered a better-than-expected full-year update and signalled a shift towards stabilisation and future growth, givin...
Dr Martens marketing 'reset' saw annual revenue and profit retreat, eyes return to growth this year
Dr Martens PLC (LSE:DOCS) reported a 10% drop in group revenue to £787.6 million for the year ended 30 March 2025, amidst a marketing 'reset'. Adjusted profit before tax fell to £34.1 million from ...
Dr Martens interims a first test for new CEO after shares stumble to all-time low
Dr Martens PLC (LSE:DOCS) shares stumbled to a new all-time low below 50p last month after the US tariff announcement, but have been tiptoeing higher in the run-up to interim results due next Thurs...
Related Companies